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Bacillus anthracis causes three forms of anthrax: inhalational, gastrointestinal, and cutaneous. Anthrax is characterized
by both toxemia, which is caused by secretion of immunomodulating toxins (lethal toxin and edema toxin), and
septicemia, which is associated with bacterial encapsulation. Here we report that, contrary to the current view of B.
anthracis pathogenesis, B. anthracis spores germinate and establish infections at the initial site of inoculation in both
inhalational and cutaneous infections without needing to be transported to draining lymph nodes, and that inhaled
spores establish initial infection in nasal-associated lymphoid tissues. Furthermore, we found that Peyer’s patches in
the mouse intestine are the primary site of bacterial growth after intragastric inoculation, thus establishing an animal
model of gastrointestinal anthrax. All routes of infection progressed to the draining lymph nodes, spleen, lungs, and
ultimately the blood. These discoveries were made possible through the development of a novel dynamic mouse
model of B. anthracis infection using bioluminescent non-toxinogenic capsulated bacteria that can be visualized within
the mouse in real-time, and demonstrate the value of in vivo imaging in the analysis of B. anthracis infection. Our data
imply that previously unrecognized portals of bacterial entry demand more intensive investigation, and will
significantly transform the current perception of inhalational, gastrointestinal, and cutaneous B. anthracis
pathogenesis.
Citation: Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL (2007) Primary involvement of pharynx and Peyer’s patch in inhalational and intestinal anthrax. PLoS
Pathog 3(6): e76. doi:10.1371/journal.ppat.0030076
Introduction
Bacillus anthracis is a sporulating Gram-positive bacterium
that causes the disease anthrax. The three forms of anthrax
reﬂect the route by which the infection is initiated:
cutaneous, gastrointestinal, and inhalational [1,2]. Anthrax
is characterized by both toxemia, which is caused by secretion
of two toxins, and septicemia, which is associated with
bacterial encapsulation. The capsule consists of poly-c-D-
glutamic acid attached to the peptidoglycan of the cell wall
and inhibits phagocytosis, functions as a non-immunogenic
surface, and is vital for full virulence [3–5]. The toxins, lethal
toxin and edema toxin, modulate host immune responses and
at high doses can cause death [6,7], but elimination of toxin
production does not alter virulence in a mouse model of B.
anthracis infection [8,9].
Surprisingly, relatively little is known about how spores
enter the host or how the dynamics of infection are affected
by the route of infection, and no animal model exists for
gastrointestinal anthrax at this time. Cutaneous anthrax, the
most common yet least lethal form of anthrax in humans, is
believed to initiate through abrasions in the skin [10].
Gastrointestinal anthrax is generally considered to be the
primary route of infection of livestock, can occur in humans,
and is caused through the ingestion of contaminated food
[2,11], yet the means by which B. anthracis crosses membrane
barriers to establish infection remains unknown. The current
model of inhalational anthrax consists of uptake of spores by
alveolar macrophage, then transport of these spores to the
draining mediastinal lymph nodes, where the spores germi-
nate and establish infectionw i t h i nt h el y m p h a t i c st o
ultimately disseminate systemically [10,12,13].
To identify the portals of initial entry and growth and to
better deﬁne the differences associated with these three
forms of B. anthracis infection, a model using in vivo
bioluminescent imaging (BLI) was developed. BLI consists
of detecting photons emitted from a cell expressing lucifer-
ase—in this case, a bacterium—within the body of a host
animal [14]. BLI analysis of B. anthracis infection provides the
advantages of tracking a dynamic infection in a dynamic
fashion, monitoring the entire mouse (allowing the discovery
of as yet-unknown locations of bacterial growth), and
detecting subclinical infections. Thus, BLI permits a kinetic
and global view of bacterial dissemination that allows the
synthesis of an integrated infection model from inoculation
to death.
We found that, contrary to the current view of B. anthracis
pathogenesis, B. anthracis spores germinate and establish
infections at the initial site of inoculation in both inhala-
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transported to draining lymph nodes. Furthermore, we found
that Peyer’s patches in the mouse intestine are the primary
site of bacterial growth after intragastric inoculation,
establishing, to our knowledge, the ﬁrst animal model of
gastrointestinal anthrax. Our data imply that previously
unrecognized portals of bacterial entry demand more
intensive investigation.
Materials and Methods
Bacterial Strains, Growth Conditions, and Reagents
All experiments were performed with a bioluminescent
derivative of B. anthracis strain 9602P (described previously in
[8]), which is a derivative of the highly virulent natural human
isolate 9602 [15], but does not produce the protective antigen
component of the toxins. Bacteria were grown on brain–
heart infusion (BHI) agar (Difco, http://www.bd.com/ds) unless
otherwise noted. Spores were produced and puriﬁed on
Radioselectan (Renograﬁn 76%; Schering, http://www.
schering.de) using previously described methods and stored
in sterile deionized water [16].
Construction and Verification of Bioluminescent B.
anthracis
The luxABCDE operon was PCR ampliﬁed from pXEN5
(pAUL-A Tn4001 luxABCDE Km
r from the Xenogen Corpo-
ration, http://www.xenogen.com) [14] using the following
oligonucleotides: LuxAF1BamXho-CGCGGATCCTCGAGCA-
GATGAAGCAAGAGGAGGACTC, which contains a BamHI
followed by an XhoI site (underlined); LuxER1Bam-
GGCGGATCCGTCGACTTAACTATCAAACGCTTCGG,
which contains a BamHI site. This PCR product was ligated
with the pGEM-T Easy vector kit (Promega, http://www.
promega.com) and transformed into Escherichia coli strain
TG1 (pIG3–40). The pIG3–40 plasmid was subsequently
puriﬁed, and the luxABCDE insert was removed via BamHI
(New England Biolabs, http://www.neb.com) digestion and
ligated into plasmid pAT113 [16], a conjugative shuttle vector
that has no Gram-positive origin of replication (pIG4–2). The
pag promoter, consisting of 1 kb of sequence upstream of the
protective antigen coding sequence, was PCR ampliﬁed from
B. anthracis DNA using the following oligonucleotides:
PPagF1EcoR1-CGAGAATTCGATGAAAATGGTAATA-
TAGCG, which contains an EcoRI site, and PPagR1Xho-
AGGGCTCGAGGTATAAAATTAAATTTATATTATATTG,
which contains an XhoI site. This PCR product was cut with
EcoRI and XhoI, ligated into pIG4–2, cut by equivalent
enzymes, and transformed into TG1 (pIG6–19). Subsequently,
pIG6–19 was introduced into B. anthracis 9602P by hetero-
gramic conjugation using previously described methods and
the conjugative E. coli strain HB101 (pRK212.1) [16], and
selected on BHI plus 5 lg/ml erythromycin, yielding strain
BIG19. Insertion into the upstream sequence of pag was
veriﬁed by both PCR and the production of light when grown
on capsulation plates in 5% CO2 at 37 8C [17]. The stability of
the lux integration was assessed by diluting cultures 1:1,000 in
R-media with 0.6% sodium bicarbonate (R-Bic) [18] at 37 8C
and 5% CO2 two times daily for 1 wk, then detecting the
presence of the lux insertion by erythromycin resistance and
luminescence. All clones contained the insert after 1 wk of
passage.
Determination of bioluminescence in comparison to
growth phase was performed by growing BIG19 in BHI plus
0.5% glycerol media overnight at 37 8C with agitation.
Subsequently, this culture was diluted into R-Bic to an
optical density (OD) of 0.05, and then incubated at 37 8Ci n
5% CO2 with agitation. At the indicated times, samples were
removed and imaged for luminescence in a 96-well plate
(Nunc, http://www.nuncbrand.com) with the IVIS 100 system
as described below, and the OD600 was measured with a
spectrophotometer (Ultrospec 3300 pro; Amersham Bioscien-
ces, http://www.gelifesciences.com).
Infection and Imaging
Six- to 10-week-old BALB/cJ mice (Charles River Labora-
tories, http://www.criver.com) were maintained under speciﬁc
pathogen-free conditions at the Pasteur Institute in com-
pliance with European animal welfare regulations. Cutaneous
infections were performed under light anesthesia by injecting
10 ll of spore suspension in PBS into the dermis of the right
ear with a 0.5-ml insulin syringe (Becton Dickinson, http://
www.bd.com) [19]. For the intravenous infection experiments,
capsulated bacteria were prepared by germinating spores in
BHI for 5 min at room temperature, centrifuging, and
incubating in R-Bic induction media at 37 8Ci n5 %C O 2
with agitation for 1.5 or 5 h. The length of bacteria in each
sample was quantiﬁed by binding formalin-ﬁxed bacteria to
polylysine-coated glass cover slips, acquiring digital micro-
scopic images, and then measuring the length of the bacteria
in each image. Injection cultures were washed with RPMI-
Glutamax (Invitrogen, http://www.invitrogen.com), and 1.4 3
10
7 and 2.0 3 10
6 colony-forming units (CFU) of the 1.5- and
5-h cultures, respectively, were injected. Seven times less CFU
of the 5-h culture was injected to account for the fact that the
5-h bacteria were approximately seven times longer than the
1.5-h bacteria, and thus CFU were not an accurate measure of
bacterial mass. Spores in 100 ll of PBS were inoculated
intragastrically by inserting a 5-cm length of polyethylene
catheter that was attached to a needle and syringe down the
esophagus and into the stomach of lightly anesthetized mice,
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Author Summary
Anthrax is caused by Bacillus anthracis, a bacterial pathogen that
forms spores, dormant bacteria that are highly resistant to
destruction. Infections initiate from the introduction of spores into
airways or damaged skin, or from the consumption of contaminated
food. Within the host, spores germinate, then bacteria secrete toxins
that cripple the immune response and sheath themselves in a
capsule that prevents them from being phagocytosed. We strove to
determine in real space and time where and when spores
introduced by these three routes of infection germinate and how
bacteria subsequently disseminate in a mouse model. This was
achieved through the development of light-emitting B. anthracis
that could be tracked inside a living mouse. Contrary to current
models, our studies indicated that spores germinated in situ in the
skin, the intestines, and the nasal passages without needing to be
transported to lymph nodes. Furthermore, bacteria disseminate
from initial sites of infection in a similar fashion, first to the draining
lymph nodes, then the spleen, and finally the lungs and blood.
These findings imply that spore interactions with local sites of entry
are critical in the development of systemic disease and that
disruption of these interactions may offer new methods of anthrax
prevention.changing the catheter for each mouse. Alternately, 18G
animal feeding needles (Popper and Sons, http://www.
popperandsons.com) were used for intragastric inoculation.
Aerosol infections were performed by delivering spores for
20 min using a Raindrop nebulizer (Tyco, http://www.tyco.
com) designed to produce 1-lm droplets of a solution
containing 1 3 10
8 spores/ml water in an all-glass, nose-only
aerosol chamber [20]. An average 3.8 6 0.3 log10 (mean 6
standard deviation [SD]) spores were found in the lungs 2 h
post-infection. Intranasal inoculation was performed in
lightly anesthetized mice by introducing 1 3 10
5 spores in
20 ll of PBS upon inhalation into the right nostril. An
average of 4.5 6 0.1 log10 (mean 6 SD) spores were found in
the lungs 2 h post-infection. Intratracheal inoculation of 1 3
10
5 spores was performed using plastic tubing as previously
described [21]. An average of 3.8 6 0.2 log10 (mean 6 SD)
spores were found in the lungs 2 h post-infection. For CFU
determination, organs were immediately placed in ice-cold
saline solution and then homogenized in a chilled glass tube,
and dilutions were plated on BHI plates. Differentiating
spores from vegetative bacteria was determined after heat
treatment of 65 8C for 30 min to kill the vegetative bacteria.
Lymph node location and nomenclature were based on
previously deﬁned standards [22]. Lungs were isolated by
cutting below the tracheobronchal bifurcation where the
bronchus enters the lobes of the lung.
Images were acquired using an IVIS 100 system (Xenogen)
according to instructions from the manufacturer. Analysis
and acquisition was performed using Living Image 2.5
software (Xenogen). Unless otherwise noted, mice were
anesthetized using a constant ﬂow of 2.5% isoﬂuorane mixed
with oxygen using an XGI-8 Gas Anesthesia System (Xeno-
gen), which allows control of the duration of anesthesia.
Images were acquired with a binning of 16. Luminescent
signals from the exterior of mice or cultures in plates were
acquired for 1 min, whereas luminescence of internal organs
during dissection was integrated for 10 s. All other photo-
graphic parameters were held constant. Quantifying photons
per second emitted by each organ was performed by deﬁning
regions of interest corresponding to the organ of interest,
while subtracting the background as deﬁned by a non-
infected animal in the same photograph.
Histology
Tissues were removed from mice with luminescence in the
organ of interest and immediately placed in 4% buffered
formalin (Labonord, Templemars, France) for standard
microscopic analysis. Skulls of mice were decalciﬁed in a
solution of 4% buffered formalin and 10% trichloroacetic
acid for approximately 2 mo for analysis of the nasal passages.
Serial 5-lm sections were stained with hematoxylin and eosin
and/or Gram [23]. Samples were analyzed by two independent
observers, one of whom was a trained pathologist.
Statistical Analysis
Statistical analysis and graphing was performed using
GraphPad Prism 4 software (http://www.graphpad.com). The
Pearson correlation coefﬁcients (r) were used to determine
the direction and magnitude of covariation between CFU
and photons/s-organ, since each X and Y value were
independent measures and are assumed to follow a Gaussian
distribution. The two-tailed p-values, a, and n are indicated
on each graph in Figure 1F.
Results
A capsulated non-toxinogenic strain of B. anthracis was
chosen for study because the capsule is vital for virulence and
is associated with dissemination [3–5], while elimination of
toxin production does not alter virulence in mouse models of
infection [8,9]. Bioluminescent B. anthracis were constructed
by integrating the luxABCDE genes from Photorhabdus lumines-
cens [14] under the control of the pag promoter, the gene for
protective antigen, a toxin component that is highly induced
under in vivo conditions [18]. These bacteria were strongly
luminescent (Figure 1A), whereas dormant spores were not
(unpublished data), reﬂecting the necessity of bacterial
metabolic activity for light production. Maximal lumines-
cence was observed during mid-log phase growth and
decreased in late-log and stationary phase (Figure 1B). Spores
derived from these bioluminescent bacteria were used in
subsequent murine bacterial dissemination models.
Cutaneous infection is the most common form of anthrax
in humans and is often limited to the site of initial infection
[1]. A cutaneous ear infection model [19] allowed efﬁcient
enumeration of CFU and high sensitivity. Luminescence at
the site of injection was detected within 120 min (Figure 1C).
This shows that spores rapidly germinate at the site of
injection and quickly become metabolically active, and that
the pag promoter is induced; these results are similar to those
obtained in tissue culture models [24,25], but unlike previous
studies that suggested that germination occurs in the drain-
ing lymph nodes [7,10]. Within 24 h of cutaneous injection of
500 spores, bioluminescence was detected in both the ear and
the superﬁcial parotid lymph node draining the ear, and was
also visible in the spleen and right lung 12 h later (Figure 1D).
Dissection conﬁrmed that the superﬁcial parotid lymph node,
spleen, both lungs, and the blood were luminescent (Figure
1E). The left lung, though luminescent, was more difﬁcult to
detect from the exterior because the heart partially blocked
the exit of photons. No other organs harbored luminescent B.
anthracis.
Differences in pigmentation, organ orientation, and tissue
depth affect how light exits the body, necessitating determi-
nation of the relationship between luminescence and
quantity of bacteria for each organ of interest. Luminescence
correlated with CFU in the ear, superﬁcial parotid lymph
node, spleen, and right lung (Figure 1F). We analyzed only the
right lung because the heart blocked a large portion of the
left lung’s emitted light. The minimum detectable quantity of
bacteria in each organ was as follows: ear, 3310
3; superﬁcial
parotid lymph node, 4 3 10
3; spleen, 2 3 10
5; and right lung,
2 3 10
4. Thus, an increase in luminescence at a particular
location can be interpreted as an increase in the bacterial
load.
Lung luminescence late in infection was unexpected from
cutaneous infections. This may indicate that bacteria growing
in distal sites enter the blood and are trapped in the lungs [5],
which is the ﬁrst ﬁne capillary bed encountered upon the
return of blood from the periphery. Bacterial entry into the
blood was simulated by intravenous injection. Luminescent
capsulated bacteria grown 5 h in inductive media, averaging
20.0 6 5.5 lm (mean 6 SD) in length and injected
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post-injection until death (Figure 2A and 2B), and killed the
mice within 40 min. Bioluminescence was not detected in any
other organs, suggesting that a majority of the bacteria were
immediately trapped in the lungs. In contrast, light emitted
by bacteria grown 1.5 h, averaging 3.2 6 0.7 lm in length, was
initially below the detection threshold. After 1 h, bio-
luminescence was detectable in the spleen, liver, and lungs.
These data suggest that bacteria from the 1.5-h culture were
initially widely distributed throughout the mouse and were
eventually localized within the spleen, liver, and lungs. This
implies that the size of bacteria entering the blood circulation
and/or growth phase inﬂuences the dissemination of bacteria
to the lungs and other organs.
Anthrax is associated with polygastric ruminant livestock,
and natural gastrointestinal infection occurs when food
contaminated with B. anthracis spores is ingested [1]. Likewise,
gastrointestinal anthrax occurs in monogastric hosts, such as
humans [2,15], yet there are no published animal models of
gastrointestinal anthrax. Intragastric inoculation of spores in
the monogastric mouse using a rigid feeding needle caused
infection of the laryngopharynx (Figure 3A), suggesting that
abrasions in the upper alimentary tract acted as portals of
infection. Intragastric inoculation with ﬂexible plastic tubing
caused true gastrointestinal infection that initiated as a
deﬁned point of luminescence in the abdomen from
approximately 24- to 33-h post-inoculation that suddenly
progressed systemically (Figure 3B). Histological examination
of the initial site of infection showed that bacterial growth
occurred in the Peyer’s patch (Figure 3C and 3D), and could
occur in Peyer’s patches throughout the small intestine
(unpublished data). Very little of the original dome archi-
tecture was maintained, with only a few lymphocytes at the
periphery. Bacterial rods, numerous polymorphonuclear
cells, necrosis, and hemorrhage were evident (Figures 3C
and S1). Similar lesions were observed in the spleen and lung
(Figure S1). Interestingly, vegetative bacteria could be
isolated from the feces 4 h post-inoculation (Figure 3E), but
only spores were found 8 h post-inoculation. These data
suggest that spores germinate in the gastrointestinal tract,
vegetative bacteria transiently colonize the lumen, and spores
are continuously shed for up to 48 h post-inoculation after a
Figure 1. Bioluminescent B. anthracis Allow Efficient Spatiotemporal
Determination of In Vivo Bacterial Location and Quantification in a
Cutaneous Model of Infection
In all figures, black and white photographs are overlaid with false color
representation of the photons s
 1 cm
 2 sr
 1; the false color scale is
incorporated into each image or group of images.
(A and B) B. anthracis carrying luxABCDE (strain BIG19) are luminescent on
solid (A) or liquid (B) capsulation medium. (B) Bioluminescence is




(C) Monitoring of light production at 10-min intervals after cutaneous
infection (1 3 10
4 spores). Image series is representative of four mice.
(D) Image series of a cutaneous infection in the ear (5 3 10
2 spores)
acquired at the indicated times (representative of 15 mice).
(E) Dissection at 52 h post-infection. Left: unopened mouse, with an
example of a measurement region of interest (ROI 1) encompassing the
right lung, and an inset of a drop of blood. Center: open peritoneum and
thorax. Right: displacement of organs to identify the sources of
luminescence.
(F) Correlation between external quantification of the photons emitted
from a defined region of interest encompassing the organ and CFU
counts for the same organs; each dot represents one organ.
doi:10.1371/journal.ppat.0030076.g001
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cutaneous model, the ensuing systemic infection spread ﬁrst
to the draining jejunal lymph nodes, then the spleen, and
ﬁnally the lungs (Figure 3B–3D).
Inhalational anthrax has a high mortality rate and is the
form of disease that is targeted when spores are weaponized
[26]. Dissemination kinetics of aerosol, intranasal, and intra-
tracheal inoculation of spores were studied. Mice infected
with aerosolized spores developed an infection in the nasal
cavity by 22 h post-infection, followed by the mandibular
lymph nodes 5 h later (Figure 4A and 4B). When bio-
luminescence was ﬁrst visible in the nasal cavity, it was not
found in the lungs and mediastinal lymph nodes (Figures 4B
and 5B), despite the effective delivery of spores into the lungs
(see Materials and Methods) and the presence of a small
quantity of heat-resistant spores in the tracheobronchal
mediastinal lymph nodes (Figure 4C). Intranasal inoculation
of spores also caused infection of the nasal cavity by 29 h
post-infection, followed by the mandibular lymph nodes 15 h
later (Figure 5A and 5B). Histologic analysis revealed that
bacteria were growing in nasal-associated lymphoid tissues
(NALTs) when bioluminescence was ﬁrst detected in the
nasopharynx (Figure 5C). Inoculation of spores by intubation
of the trachea caused two distinctly different patterns of
infection. In the ﬁrst form, the primary site of early
luminescence was the mandibular lymph nodes (Figure 6A),
likely representing initiation of infection by spores that were
expelled from the lung by coughing and/or the ciliary
escalator [27]. The second form of infection initiated in the
larynx within 22 h post-infection and progressed to systemic
disease within 9 h (Figure 6B and 6C). Intubation of the
trachea (via the larynx) may cause abrasions that allowed
direct mucosal infection, as previously noted [12], and which
we also observed in the gastrointestinal model (Figure 3A). As
in the cutaneous and intragastric models, the biolumines-
cence in all inhalational models progressed from the site of
initial infection to systemic distribution (Figures 4A and 5A).
Discussion
Real-time analysis of capsulated B. anthracis infection has
allowed the synthesis of a coherent model of murine infection
from initial infection to death that modiﬁes the current
paradigm of B. anthracis dissemination; primary bacterial
growth is limited to locations associated with the inoculation
site, followed by dissemination to the draining lymph nodes,
then the spleen, and ultimately the lungs and blood. In
agreement with J. M. Ross’s seminal study of inhalational
infection of guinea pigs [12], our data indicated no bacterial
growth within the lungs at early stages of infection in
Figure 2. Bacterial Growth Phase Affects Hemotagenous Dissemination
(A and B) Luminescent capsulated bacteria grown for 1.5 or 5 h in R-Bic medium, averaging either 3.2 6 0.7 lm (solid bars, ‘‘Short Bacteria’’) or 20.0 6
5.5 lm (empty bars, ‘‘Long Bacteria’’) in length (mean 6 SD), respectively, were used to infect the mice in (B). The dotted lines indicate the median
bacilli length for each bacterial population. Inset photographs depict phase-contrast microscopic images of short and long bacteria with the
corresponding scale.
(B) Mice infected intravenously with either short or long capsulated luminescent bacteria (see Materials and Methods), represented in (A), were analyzed
as in Figure 1, at the indicated times. The scale at the right applies to all images of mice.
doi:10.1371/journal.ppat.0030076.g002
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that intravenous bacteria rapidly associate with the lungs,
support the hypothesis that vegetative bacteria arrive in the
lungs via the blood [5,28], rather than in situ growth from
spores.
Unexpectedly, our results showed that metabolically active
bacteria were found solely in the nasopharynx and its
associated lymph nodes early in infection, which is contrary
to previous studies that suggested that bacteria multiply
primarily in the mediastinal lymph nodes at the initiation of
infection [12,13]. These previous studies note that there were
incisions or trauma to the airways caused by experimental
technique, which makes interpretation of early events in the
infection difﬁcult, as we found that abrasions were prefer-
ential portals of infection (Figures 3A, 6B, and 6C) and may
allow bacterial access to the lymph nodes via direct transport
to the lymphatics across the damaged epithelial barrier.
Indeed, in Ross’s study, spores in transit to the regional lymph
node are only observed in infections initiated through
intratracheal intubation, a technique that she noted to cause
tracheal injury, and were not observed in transit when a non-
invasive spore aerosol was used [12]. BLI analysis of B.
anthracis infection provided the advantage of differentiating
these unintended sites of infection from those infections
initiated in targeted tissues.
Furthermore, other studies that support mediastinal
growth have derived conclusions from autopsy of animals
after death caused by the infection [28,29], which could
confound interpretation, since we observed a sudden
increase in bacteria in the lungs late in infection. The
bacteria found in the mediastinal lymph nodes late in
infection or at death could otherwise be explained as
originating from the population of bacteria that spread to
the lungs hematogenously. Regardless of the method of spore
delivery (cutaneous, gastrointestinal, intravenous, or by
inhalation) we found that the lung eventually contained large
numbers of bacteria that may subsequently drain into the
mediastinal lymph nodes. Supporting this interpretation,
Zaucha et al. noted signiﬁcant mediastinal lymph node
involvement in rabbits infected subcutaneously [28]. Thus,
our investigation also implies that the timing of when tissue
samples are taken is vital, indicating an additional advantage
of using dynamic models of infection such as BLI.
Our ﬁndings demonstrate that a severe infection with
highly metabolically active bacteria develops in the naso-
pharynx of mice at a time in the infection when low to
undetectable quantities of spores are in the mediastinal
lymph nodes. Thus, it is reasonable to question the relevance
of the bacteria found in the mediastinal lymph nodes to the
subsequent disseminated disease when at an earlier time-
point a much larger infection is occurring in the nasophar-
ynx. Moreover, large quantities of spores can persist in the
lungs for long periods without causing disease ([30]; unpub-
lished data), also bringing into question the relative efﬁcacy
of initiation of infection from lung tissues. Additionally, we
observed bacteria growing within the NALT, which may
indicate that bacteria can directly invade tissues of the
nasopharynx without needing to be transported by alveolar
macrophages to the lymphatics, as previously postulated [31].
Indeed, there has been growing evidence that B. anthracis can
directly infect non-phagocytic cells [32]. Therefore, our
results suggest that B. anthracis–host interactions in the
Figure 3. Initial Involvement of Peyer’s Patches or Oropharynx in
Gastrointestinal B. anthracis Infection
(A–E) BIG19 (1310
8) spores were inoculated intragastrically using a rigid
feeding needle (A) or a flexible plastic tube (B–E), yielding distinctly
different patterns of infection. (A) Left: image series at the indicated
times. Right: dissection of the anterior of the neck of the same mouse,
displaying luminescence in the laryngopharynx.
(B) Infection of the lower digestive tract at the indicated times. Image
series is representative of 23 mice.
(C) Tissue sections of an infected Peyer’s patch, stained with hematoxylin
and eosin (H&E) (left and middle) and Gram (right) at low and high
magnification (location indicated by the black box). The arrows in the
middle image point to numerous neutrophils infiltrating the Peyer’s
patch.
(D) Dissection of the mouse in (B) to confirm sources of luminescence. JL,
jejunal lymph node; LL, left lung; PP, Peyer’s patch; RL, right lung; S,
spleen.
(E) Total CFU of B. anthracis (Unheated) or spores only (Heated) were
enumerated at the indicated times from the feces of mice inoculated
intragastrically (mean 6 standard error of the mean, n ¼ 4).
doi:10.1371/journal.ppat.0030076.g003
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and should be the focus of future research.
The data obtained through gastric inoculation of spores
reﬂect many of the characteristics of human gastrointestinal
anthrax, including two forms of infection (oropharyngeal and
lower gastrointestinal), intestinal abscesses, hemorrhage,
necrosis, and epithelial barrier breakdown [2]. To our
knowledge, this is the ﬁrst establishment of a mouse model
of gastrointestinal B. anthracis infection. This model should
prove particularly useful in addressing questions regarding B.
anthracis pathogenesis since mice offer a wide variety of
immunologic and genetic tools that permit the determination
of speciﬁc host factors involved in host–pathogen interac-
tions. Furthermore, we observed that while abrasions to the
Figure 4. Aerosolized Spores Cause Nasopharyngeal Infection without Growth in Mediastinal Lymph Nodes
(A) Image series of a mouse infected by aerosolized BIG19 spores. Images are representative of eight mice.
(B) Dissection of a mouse (bottom left) early in infection (28 h) with the corresponding external image (top left) showing bioluminescence in the nasal
cavities and mandibular lymph node, the open thorax (center), and with the heart and lungs displaced (right). Arrows point to the mediastinal lymph
nodes (MLN) that do not display luminescence. H, heart; L, liver; LL, left lung; RL, right lung; SLN, submandibular lymph nodes; T, thymus.
(C) Total CFU of B. anthracis (Unheated) or spores only (Heated) were enumerated in the lungs and tracheobronchal mediastinal lymph nodes (MLN)
when luminescence was detected in the nasopharynx. Each circle represents the CFU derived from one mouse. Solid lines indicate the log-mean. Dotted
lines represent the detection limits for the different organs. There was no significant difference between unheated or heated samples from the lungs (p
¼ 0.62) and mediastinal lymph nodes (p ¼ 0.90) (Student’s t-test). Data are derived from two independent experiments.
doi:10.1371/journal.ppat.0030076.g004
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tion also occurred in the absence of mucosal damage, albeit
with slower kinetics. Indeed, it has been hypothesized that the
tendency of anthrax outbreaks to begin after drought
conditions is due to abrasions in the mucosa caused by the
consumption of sharp dried plants [11]. Similarly, preexisting
lesions may predispose humans to infection [28,29]. The
means by which B. anthracis invades the Peyer’s patch in the
absence of mucosal damage remains unknown, but may
include uptake by M cells or dendritic cells [33].
In vivo bioluminescent imaging of B. anthracis has numer-
ous possible applications. Some of these applications include
real-time visualization of the effects of antibiotic therapy at
different stages of B. anthracis infection, which is of particular
interest because anthrax diagnosis often occurs at late stages
of the disease, leading to ineffective treatment [11]. Another
potential application is the analysis of different anti-anthrax
vaccination strategies to determine where, when, and how
efﬁciently the induced protective adaptive immunity termi-
nates infection.
Taken together, the data presented in this manuscript
suggest that the current paradigm of B. anthracis infection
should be revisited. Unexpectedly, we found that B. anthracis
spores germinate and establish infections at the initial site of
inoculation in both inhalational and cutaneous infections,
and that mice initially develop infections in Peyer’s patches
upon intragastric inoculation of spores. Since the elimination
of toxin production does not affect virulence in the mouse
model of infection [8,9], one would predict that our models
are valid representations of infections with toxinogenic
Figure 5. Bacterial Growth Occurs in NALTs after Intranasal Inoculation
(A) Image series of a mouse infected by intranasal inoculation of 1 3 10
5 spores at the indicated times. Image series is representative of 12 mice.
(B) Images of a mouse infected for 44 h. Left: external right side. Center: opened anterior of the neck. Right: thorax with lungs and heart removed.
Arrows point to the mediastinal lymph nodes (MLN) that do not display luminescence. SLN, submandibular lymph nodes.
(C) Gram-stained transverse tissue sections of a bioluminescent nasal cavity 44 h post-infection. Left: 203 image of the nasal cavity. Center and right:
1003 and 4003 images, respectively, corresponding to the location indicated by the black boxes in the 203 and 1003 images, respectively. Infected
NALT displayed breakdown of the lymphoid tissue structure, infiltration of numerous polymorphonuclear cells, several areas of light hemorrhage, and
numerous Gram-positive bacterial rods, and also an undamaged epithelial layer.
doi:10.1371/journal.ppat.0030076.g005
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Novel Portals for B. anthracis Infectioncapsulated strains, though whether differences will be seen in
the presence of both toxin production and capsule synthesis
remains to be determined experimentally.
Supporting Information
Figure S1. Histological Analysis of Bioluminescent Organs Show
Infection, Inﬂammation, Necrosis, and Hemorrhaging
Sections derived from intragastrically infected mice after 38 h
(Peyer’s patch, spleen, and lung) or intranasally infected mice after
48 h (mandibular lymph node). Left and center: hematoxylin and
eosin (H&E) staining. The major observations were: in the Peyer’s
patch, enlargement, breakdown of the dome epithelial barrier,
inﬁltration of numerous polymorphonuclear cells, and the presence
of necrosis; in the infected lymph node, extensive necrosis; in the
spleen, hemorrhaging and necrosis; in the infected lung, congestion,
inﬂammation, and hemorrhaging. Right: Gram staining. Numerous
Gram-positive bacteria are visible in all samples. Bacteria in the lung
are restricted to lung tissues and are not found in the alveolar space.
Found at doi:10.1371/journal.ppat.0030076.sg001 (10 MB PDF).
Figure 6. Inoculation by Intratracheal Intubation Leads to Two Different Patterns of Infection
(A) Images of two representative mice infected 46 (left) and 52 h (right) after intratracheal inoculation of 1310
5 BIG19 spores that developed infection
in the oropharynx. Luminescence is detected in the oropharynx, spleen, and lung.
(B) Time-lapse image series of a mouse with infection of the larynx. Images are representative of 18 intratracheally infected mice.
(C) Dissection of a mouse with laryngeal infection, with (left) or without (center) the luminescence overlay. Right: an image of the respiratory tract ex
vivo.
Found at doi:10.1371/journal.ppat.0030076.g006
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The National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov) accession numbers for the genes and gene products
discussed in this paper for B. anthracis are protective antigen, pagA
(AF268967); lethal factor, lef (M29081); Edema factor, cya (M24074);
capsule synthesis operon, capBCAD (D85765), and capE, which can be
found on the sequence of plasmid pX02 (AF188935). The number for
the P. luminescens luciferase operon, luxCDABE, is M90093.
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